Kyverna Taps Rare Disease Commercial Chief as It Preps First CAR T Launch
Event summary
- Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer on May 4, 2026.
- Dac brings 30 years of commercial leadership experience in neurology and rare diseases.
- She will lead the commercial strategy for miv-cel, Kyverna's lead CAR T therapy for stiff person syndrome.
- Dac received an inducement grant of 300,000 stock options, vesting over four years.
- Kyverna is preparing for a potential first approval of miv-cel in stiff person syndrome.
The big picture
Kyverna's appointment of Nadia Dac underscores its shift from clinical development to commercialization, a critical phase for biotech companies. Dac's track record in launching rare disease therapies positions Kyverna to navigate the complex regulatory and market dynamics of bringing miv-cel to patients. The move signals confidence in securing a first approval for stiff person syndrome and building a multi-indication neuroimmunology franchise.
What we're watching
- Launch Execution
- Whether Kyverna can successfully transition to a commercial-stage organization with Dac's leadership.
- Market Expansion
- The pace at which Kyverna expands miv-cel into other neuroimmunology diseases after the initial approval.
- Competitive Positioning
- How Kyverna differentiates miv-cel in a landscape with limited treatment options for autoimmune diseases.